Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Ovarian Neoplasms

  Free Subscription


01.11.2021

2 Am J Obstet Gynecol
1 Am J Surg Pathol
1 Ann Oncol
1 BMC Cancer
4 Gynecol Oncol
1 Int J Cancer
3 Int J Gynaecol Obstet
1 Lancet Oncol
1 Oncol Rep
1 PLoS Comput Biol


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Am J Obstet Gynecol

  1. MARCHOCKI Z, Cusimano MC, Clarfield L, Rachel Kim S, et al
    Sentinel lymph node biopsy in high-grade endometrial cancer: a systematic review and meta-analysis of performance characteristics.
    Am J Obstet Gynecol. 2021 May 28. pii: S0002-9378(21)00602.
    PubMed         Abstract available

  2. VAN WEELDEN WJ, Lalisang RI, Bulten J, Lindemann K, et al
    IMPACT OF HORMONAL BIOMARKERS ON RESPONSE TO HORMONAL THERAPY IN ADVANCED AND RECURRENT ENDOMETRIAL CANCER.
    Am J Obstet Gynecol. 2021 May 18. pii: S0002-9378(21)00554.
    PubMed         Abstract available


    Am J Surg Pathol

  3. RODRIGUEZ M, Kang EY, Farrington K, Cook LS, et al
    Accurate Distinction of Ovarian Clear Cell From Endometrioid Carcinoma Requires Integration of Phenotype, Immunohistochemical Predictions, and Genotype: Implications for Lynch Syndrome Screening.
    Am J Surg Pathol. 2021 Sep 16. pii: 00000478-900000000-97128.
    PubMed         Abstract available


    Ann Oncol

  4. COLOMBO N, Ledermann JA
    Updated treatment recommendations for newly diagnosed epithelial ovarian carcinoma from the ESMO Clinical Practice Guidelines.
    Ann Oncol. 2021 Jul 14. pii: S0923-7534(21)02182.
    PubMed        


    BMC Cancer

  5. GERNIER F, Ahmed-Lecheheb D, Pautier P, Floquet A, et al
    "Chronic fatigue, quality of life and long-term side-effects of chemotherapy in patients treated for non-epithelial ovarian cancer: national case-control protocol study of the GINECO-Vivrovaire rare tumors INCa French network for rare malignant ovaria
    BMC Cancer. 2021;21:1147.
    PubMed         Abstract available


    Gynecol Oncol

  6. MANYAM M, Stephens AJ, Kennard JA, LeBlanc J, et al
    A phase 1b study of intraperitoneal oncolytic viral immunotherapy in platinum-resistant or refractory ovarian cancer.
    Gynecol Oncol. 2021 Oct 19. pii: S0090-8258(21)01513.
    PubMed         Abstract available

  7. HARRISON R, Zighelboim I, Cloven NG, Marcus JZ, et al
    Secondary cytoreductive surgery for recurrent ovarian cancer: An SGO clinical practice statement.
    Gynecol Oncol. 2021 Oct 19. pii: S0090-8258(21)01452.
    PubMed        

  8. TREDAN O, Provansal M, Abdeddaim C, Lardy-Cleaud A, et al
    Regorafenib or Tamoxifen for platinum-sensitive recurrent ovarian cancer with rising CA125 and no evidence of clinical or RECIST progression: A GINECO randomized phase II trial (REGOVAR).
    Gynecol Oncol. 2021 Oct 22. pii: S0090-8258(21)01402.
    PubMed         Abstract available

  9. WALTER A, Rocconi RP, Monk BJ, Herzog TJ, et al
    Gemogenovatucel-T (Vigil) maintenance immunotherapy: 3-year survival benefit in homologous recombination proficient (HRP) ovarian cancer.
    Gynecol Oncol. 2021 Oct 23. pii: S0090-8258(21)01422.
    PubMed         Abstract available


    Int J Cancer

  10. ISLAM S, Dutta P, Sahay O, Gopalakrishnan K, et al
    Feedback-regulated transcriptional repression of FBXO31 by c-Myc triggers ovarian cancer tumorigenesis.
    Int J Cancer. 2021 Oct 27. doi: 10.1002/ijc.33854.
    PubMed         Abstract available


    Int J Gynaecol Obstet

  11. MCCLUGGAGE WG
    Progress in the pathological arena of gynecological cancers.
    Int J Gynaecol Obstet. 2021;155 Suppl 1:107-114.
    PubMed         Abstract available

  12. WICHMANN IA, Cuello MA
    Obesity and gynecological cancers: A toxic relationship.
    Int J Gynaecol Obstet. 2021;155 Suppl 1:123-134.
    PubMed         Abstract available

  13. BEREK JS, Renz M, Kehoe S, Kumar L, et al
    Cancer of the ovary, fallopian tube, and peritoneum: 2021 update.
    Int J Gynaecol Obstet. 2021;155 Suppl 1:61-85.
    PubMed         Abstract available


    Lancet Oncol

  14. BANERJEE S, Moore KN, Colombo N, Scambia G, et al
    Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet Oncol. 2021 Oct 26. pii: S1470-2045(21)00531.
    PubMed         Abstract available


    Oncol Rep

  15. CHEN J, Chen H, Pan L
    SIRT1 and gynecological malignancies (Review).
    Oncol Rep. 2021;45.
    PubMed         Abstract available


    PLoS Comput Biol

  16. ZHU K, Cai L, Cui C, de Los Toyos JR, et al
    Single-cell analysis reveals the pan-cancer invasiveness-associated transition of adipose-derived stromal cells into COL11A1-expressing cancer-associated fibroblasts.
    PLoS Comput Biol. 2021;17:e1009228.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: